Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Summary
S06925 would require most New York health insurance policies and certain health coverage arrangements to cover FDA-approved or FDA-authorized antiviral therapeutics for the treatment of COVID-19 when prescribed by a licensed health care provider. The bill applies to individual, group, blanket, and certain nonprofit health plans, and it also extends to Medicaid/medical assistance coverage under the social services law.
The measure prohibits deductibles and coinsurance for this coverage, meaning patients would receive the antiviral drugs at no cost under the required benefit. It also allows insurers and programs to require use of an available manufacturer or government assistance program first if the patient is eligible for free or reduced-cost access through that source. The bill would take effect on the first day of January after enactment and would apply to policies and contracts issued, renewed, modified, altered, or amended on or after that date.
Impact
The bill would amend the Insurance Law and Social Services Law to create a mandated coverage benefit for COVID-19 antiviral therapeutics across a broad range of private health insurance products and public medical assistance coverage. It would bar cost-sharing for the covered drugs in most commercial plans and require no-cost coverage in the medical assistance program, while preserving coordination with manufacturer or government assistance programs where available. Insurers, health plans, and Medicaid administrators would need to update benefit designs and claims processing to comply with the new mandate.
Sentiment
No committee transcript or vote record is available in the provided materials, so there is no documented floor or committee debate to gauge support or opposition. Based on the bill text and caption, the measure appears consumer-protective and public-health oriented, aiming to reduce out-of-pocket costs for COVID-19 treatment. The absence of recorded votes or discussion means the overall sentiment cannot be measured beyond the bill’s apparent intent.
Contention
The main policy issue embedded in the bill is cost and coverage responsibility: insurers and public programs would be required to pay for COVID-19 antivirals without deductibles or coinsurance, which could raise concerns about premium or program costs. A secondary point of contention could be the bill’s allowance for insurers to require use of manufacturer or government assistance programs first, which may be seen as a cost-containment measure by payers but as an administrative hurdle by patient advocates. No specific opposing lawmakers, stakeholders, or negotiated amendments are identified in the provided record.
Same As
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Dementia treatment medical services and prescription medications coverage requirement provision and step therapy requirements for medical assistance provision
Coverage of medical services and prescription medications for the treatment of dementia required, and step therapy requirements for medical assistance modified.
Amends the current law on health insurance coverage for fertility diagnostic care, standard fertility preservation services, and fertility treatment and requires coverage for any medically necessary ovulation-enhancing drugs and medical services.
Establishes deadline for DEP implementation of prescribed burn program, and provides for establishment of prescribed burn acreage goals, schedules, calendars, training program, and mobile deployment units to provide on-site prescribed burn training and assistance.